|
|
 |
| |
|
|
|
Business Advisers
Professor William J. Rutter, Ph.D.
UCSF, Chiron Founder
|
|
In 1981 Rutter and two colleagues
founded Chiron in an effort to explore
the business applications and potential
solutions to problems of human disease.
He conducted Hepatitis B research, which
resulted in development with Chiron and
Merck of the vaccine for Hepatitis B,
the first recombinant vaccine. Also at
Chiron, he worked on the first
sequencing of the HIV genome, and
discovered, sequenced, and cloned the
Hepatitis C virus. This opened the way
for the development of diagnostic tests,
therapeutic drugs, and vaccines against
these viruses, and pioneered other
projects aimed at therapy of cancer and
metabolic disease. He founded
Synergenics, L.L.C., a consortium of
commonly owned but independent biotech
companies organized to offer a
cost-effective approach to startups in
the life sciences industry. In late
2007, UCSF announced that Mission Bay’s
newest building, designed to facilitate
communications between industry and the
campus, would be named the “William
Rutter Center”. William J. Rutter earned
a B.S. in biochemistry from Harvard
University. He earned an M.S. from the
University of Utah and his Ph.D. in
biochemistry at the University of
Illinois. |
|
|
Cheri Walker, Ph.D.
Operating Executive, SFW Capital
Partners
|
|
Previously Dr. Walker was Senior Vice
President of Corporate Development
at Charles River Labs (NYSE: CRL) a
leading contract research
organization. Prior to Charles
River, Dr. Walker was Vice
President, Mergers and Acquisitions
for Qiagen N.V (NASDAQ: QGEN), a
leader in life science tools and
molecular diagnostics. She was also
previously a Vice President of the
Proteomics Business Segment and Vice
President of corporate development
for Life Technologies (NASDAQ: LIFE) and a Vice President
in the equity research group at
Deutsche Bank covering Life Science
Tools. Dr. Walker has a BA in
Biology from Swarthmore College and
a Ph.D. in Human and Molecular
Genetics from Baylor College. |
|
Stephen Sun Chiao, Ph.D.
Managing Partner, Sycamore Ventures
|
|
Dr. Chiao is a Managing
Partner of Sycamore Ventures in charge
of technology investment. Since 2002, he
has served on the investment committee
for both SVC and AsiaStar investment
funds. Over the last 15 years, he has
served on the Board of Directors for
many companies. Prior to joining
Sycamore, Dr. Chiao held various senior
management & technical positions at
Gould/AMI, Hewlett-Packard and Varian
Associates. He also advised several
high-tech startups and investments in
Silicon Valley. Dr. Chiao serves on the
boards of ACM, Corrigo and TeleNav. He
also serves as a senior advisor to AOI,
Aplus Flash, illuminate, and Solargiga
Energy.
|
|
|
Scientific Advisers |
|
|
Professor Nouri Neamati, Ph.D.
USC,
School of Pharmacology Pharmacy |
|
Neamati's work primarily focuses on cancer and
HIV. He currently has compounds at various
stages of development - from theoretical to in
vitro to in vivo. Some of these compounds have
been shown to work in experimental mouse disease
models while exhibiting no toxicity.
Collaborating with colleagues at the Norris
Cancer Center, Neamati aims to take these
promising therapeutics into clinical trials. His
research has also developed compounds for
diabetes, and through collaboration, has
discovered a drug for muscular dystrophy that is
currently in the early stages of development.
Dr. Neamati obtained a Ph.D. in biomedical
sciences from the University of Texas Graduate
School of Biomedical Sciences and M.D. Anderson
Cancer Center, Houston, Texas. From 1995-2000,
he was a postdoctoral fellow and a research
fellow at the National Institutes of Health. In
September 2000, he joined the University of
Southern California School of Pharmacy with a
joint appointment at the Norris Comprehensive
Cancer Center.
|
|
|
Professor Yun Yen, M.D., Ph.D.
Chair, Molecular Pharmacology,
City of Hope |
Dr. Yen is a Full Professor and Chair of the
Department of Molecular Pharmacology and
Staff Physician of Medical Oncology, and
Director of the Molecular Pharmacology
Department at the Beckman Research Institute
of the City of Hope in Duarte, California.
He leads the translational research at City
of Hope. The translation work focuses on
early marker detection, genome medicine, and
targeted therapy. He serves several
positions at City of Hope which include
Associate Director for Translational
Research, Comprehensive Cancer Center; Dr. &
Mrs. Allen Y. Chao Chair in Developmental
Cancer Therapeutics, Endowed Chair;
Co-leader, Developmental Cancer Therapeutics
Program, Comprehensive Cancer Center;
Professor and Chair, Molecular Pharmacology;
and Interim Chair, Medical Oncology &
Therapeutics Research. Dr Yen obtained his
Ph.D. from Thomas Jefferson University,
Philadelphia, PA, Pathology & Cell Biology,
and his M.D. from Taipei Medical College,
Taipei, Taiwan.
|
|
|
|
|
|
 |
|
10020 Pioneer Blvd.,
Suite 102, Santa Fe Springs, CA 90670, USA, Tel: 562-801-0050, Fax:
562-801-0060
Applied BioCode, Inc.,
Copyright 2008-2012. All Rights Reserved. |
|
